Advertisement

Picture EBD Group BioPharm America 2017 BPA Boston MA Startup September 600x60px
Document › Details

CRISPR Therapeutics AG. (4/24/14). "Press Release: CRISPR Therapeutics Raises $25 Million in Series A Financing and Announces Founding Team of World-renowned Academics and Clinicians". Basel.

Organisations Organisation CRISPR Therapeutics AG (Nasdaq: CRSP)
  Group CRISPR Therapeutics (Group)
  Organisation 2 Versant Ventures
Products Product CRISPR gene editing technology
  Product 2 venture capital
Index term Index term CRISPR Therapeutics–Versant Ventures: investment, 201404 financing round Series A $25m from Versant Ventures
Persons Person Novak, Rodger (CRISPR Therapeutics 201404 CEO before Sanofi + Nabriva GmbH)
  Person 2 Woiwode, Tom (Versant Ventures 201404 before Synosis + Xenoport)
     


CRISPR Therapeutics, a biopharmaceutical company focused on the breakthrough gene-editing technology CRISPR-Cas9, has raised $25 million in a series A investment from Versant Ventures. The company today also announced a founding team comprising high-profile experts in diverse fields of science including CRISPR-Cas9, genome editing, stem cell biology, advanced drug delivery technologies, RNA interference and gene silencing.

The funding and the team's collective expertise will allow CRISPR Therapeutics to translate its technology into important new gene medicines that have the potential to cure serious genetic diseases at the molecular level.

Cas9 is an enzyme that can be easily programmed with RNA to cut DNA at targeted sites within the genome,1-2 enabling the deletion, insertion or correction of target genes with surgical precision. It allows scientists and clinicians to mutate genes of interest and to correct specific target genes, to tackle both recessive and dominant genetic diseases. CRISPR-Cas9 genome editing offers significant advantages over traditional gene therapy approaches, which to date have only been useful in correcting some recessive genetic disorders.

"The efficiency and ease of use of CRISPR-Cas9 have led to the scientific community rapidly adopting the technology on an unprecedented scale," said Dr Rodger Novak, Chief Executive Officer of CRISPR Therapeutics. "We look forward to leveraging this potentially game-changing technology to provide new gene medicines to patients suffering from serious diseases."

Dr Tom Woiwode, Venture Partner of Versant Ventures, said: "We believe that CRISPR Therapeutics has immense potential, as it is uniquely positioned to translate this technology into human therapeutics, thanks to its foundational intellectual property and its multi-disciplinary team of experts, including senior industry executives, world-renowned academics, and clinicians."


CRISPR Therapeutics' scientific founders are:

> Dr Daniel Anderson, the Sam Goldblith Associate Professor at the Massachusetts Institute of Technology and an intramural member of the Koch Institute for Integrative Cancer Research

> Dr Emmanuelle Charpentier, a professor at the Helmholtz Centre for Infection Research and Hannover Medical School, Germany and the Laboratory for Molecular Infection Medicine at Umeå University, Sweden, who holds an Alexander von Humboldt professorship for research in Germany

> Dr Chad Cowan, an associate professor at Harvard University in the Department of Stem Cell and Regenerative Biology, and at Massachusetts General Hospital, with appointments in the Center for Regenerative Medicine, the Cardiovascular Research Center and the Center for Human Genetics Research

> Dr Craig Mello, a Nobel prize-winning investigator at the Howard Hughes Medical Institute, the Blais University Chair in Molecular Medicine, and co-director of the RNA Therapeutics Institute at the University of Massachusetts Medical School

> Dr Matthew Porteus, an associate professor of pediatrics, Department of Pediatrics; Divisions of Hematology/Oncology and Human Gene Therapy, at Stanford School of Medicine


CRISPR Therapeutics has secured rights to the foundational intellectual property covering the use of CRISPR-Cas9 genome editing in human therapeutics. The company in-licensed the technology from Dr Charpentier, who co-invented the CRISPR-Cas9 technology.1-2

"CRISPR-Cas9 has truly democratized genome editing, with many areas of research being transformed due to the technology's ease of use and broad applicability," said Dr Charpentier. "The collective efforts of the broader academic research community are in turn driving tremendous progress in the field."


About CRISPR Therapeutics

CRISPR Therapeutics is a biopharmaceutical company created to translate CRISPR-Cas9, a breakthrough gene-editing technology, into transformative medicines for serious human genetic diseases. Its vision is to cure serious human diseases at the molecular level using CRISPR-Cas9. CRISPR Therapeutics is a Swiss company with operations in London, UK. www.crisprtx.com


About Versant Ventures

Versant Ventures is a leading venture capital firm that specializes in investments in game-changing medical devices, biopharmaceuticals, and other life science opportunities. Founded in 1999, the firm consists of an experienced team of managing directors committed to helping entrepreneurs build successful companies that impact healthcare and improve quality of life. Versant has offices in the US, Canada and Switzerland. www.versantventures.com


Media contact

Pete Chan
Tel: +44 (0) 207 034 3208
Email: pete.chan@tudor-reilly.com


References

1. Deltcheva, E et al. (2011). CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. Nature, (471), 602-607.

2. Jinek, M and Chylinski, K et al. (2012). A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science, (337), 816-821.

   
Record changed: 2017-04-02

Advertisement

Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 600x60px

More documents for CRISPR Therapeutics (Group)


To subscribe to our free, monthly newsletter for the life sciences in German-speaking Europe (DE, AT & CH), please send an e-mail to info@iito.de and simply fill the subject line with the word »LSG newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture BIO Deutschland EBDC 2017 Heidelberg 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px Picture BIO Deutschland EBDC 2017 Heidelberg 120x240px Picture EBD Group BioPharm America 2017 BPA Boston MA Startup September 120x80px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture BIO Deutschland EBDC 2017 Heidelberg 120x240px Picture EBD Group BioPharm America 2017 BPA Boston MA Startup September 120x80px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px